Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leronlimab - CytoDyn

Drug Profile

Leronlimab - CytoDyn

Alternative Names: PA-14; PRO-140

Latest Information Update: 09 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Progenics Pharmaceuticals
  • Developer CytoDyn; Progenics Pharmaceuticals; The Scripps Research Institute
  • Class Antineoplastics; Antiretrovirals; Hepatoprotectants; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration HIV infections
  • Phase III HIV-1 infections
  • Phase II Breast cancer; Graft-versus-host disease; Non-alcoholic steatohepatitis
  • Preclinical Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Pancreatic cancer; Prostate cancer
  • Phase Unknown Malignant melanoma

Most Recent Events

  • 01 Oct 2019 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (Parenteral)
  • 01 Oct 2019 Phase-III clinical trials in HIV-1 infections (Monotherapy, Treatment-experienced) in USA (SC)
  • 01 Oct 2019 The US FDA approves IND application for leronlimab in Non alcoholic steatohepatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top